LNC Therapeutics is a venture-backed company that conducts fundamental research, preclinical studies, and clinical trials to develop innovative gut microbiota directed drugs for treating obesity and associated cardiometabolic diseases. The company collaborates with medical experts worldwide to ensure the highest standards of drug development. LNC Therapeutics has raised €16.5 million so far, including €1.5 million in grants from French BPI and Aquitaine Region, to continue its research programs. Its goal is to bring the next generation approach to treat obesity and cardiometabolic diseases.